MedPath
HSA Approval

SUBUTEX SUBLINGUAL TABLETS 8 mg

SIN11275P

SUBUTEX SUBLINGUAL TABLETS 8 mg

SUBUTEX SUBLINGUAL TABLETS 8 mg

February 3, 2000

ZUELLIG PHARMA PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZUELLIG PHARMA PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

N02AE01

buprenorphine

Manufacturer Information

ZUELLIG PHARMA PTE. LTD.

RECKITT BENCKISER HEALTHCARE (UK) LTD

Active Ingredients

BUPRENORPHINE HCl EQV BUPRENORPHINE

8 mg

Buprenorphine

Documents

Package Inserts

Subutex Tablet PI.pdf

Approved: November 18, 2016

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SUBUTEX SUBLINGUAL TABLETS 8 mg - HSA Approval | MedPath